Breast Cancer Clinical Trials in Baltimore, Maryland

22 studies are recruiting for breast cancer in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

    This is a multicenter, multi-arm, biomarker-stratified trial designed to evaluate biomarker-directed therapies in patients with estrogen receptor-positive/hormone receptor-negative (ER+/HR-) and triple-negative (TN) metastatic breast cancer (MBC). The trial integrates both retrospective and prospec…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
    Locations
    6 in total
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07340541 on ClinicalTrials.gov

  2. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Johns Hopkins University, Baltimore, Maryland
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  3. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mercy Medical Center, Baltimore, Maryland
    Locations
    567 in total
    Run by
    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

  4. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

    This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Baltimore, Maryland
    Locations
    67 in total
    Run by
    AstraZeneca

    See if you can join NCT05123482 on ClinicalTrials.gov

  5. Cardiometabolic Screening Program

    This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional …

    Stage
    Not phased
    Ages
    18 and older
    Site
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT05386719 on ClinicalTrials.gov

  6. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Maryland, Baltimore, Maryland
    Locations
    241 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06790693 on ClinicalTrials.gov

  7. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Baltimore, Maryland
    Locations
    231 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

  8. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage
    Phase 3
    Ages
    18 to 60
    Site
    University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
    Locations
    1261 in total
    Run by
    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

  9. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

    This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Baltimore, Maryland
    Locations
    320 in total
    Run by
    AstraZeneca

    See if you can join NCT06103864 on ClinicalTrials.gov

  10. E-Mindfulness Approaches for Living After Breast Cancer

    NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

    Stage
    Phase 3
    Ages
    18 to 50
    Site
    Maryland Proton Treatment Center, Baltimore, Maryland
    Locations
    383 in total
    Run by
    NRG Oncology

    See if you can join NCT06748222 on ClinicalTrials.gov

  11. Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

    The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wal…

    Stage
    Phase 3
    Ages
    19 and older
    Site
    Maryland Proton Treatment Center, Baltimore, Maryland
    Locations
    9 in total
    Run by
    Proton Collaborative Group

    See if you can join NCT05856773 on ClinicalTrials.gov

  12. EXoPERT EMERALD Clinical Study

    The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicl…

    Stage
    Not phased
    Ages
    45 and older
    Site
    John Hopkins University, Baltimore, Maryland
    Locations
    9 in total
    Run by
    EXoPERT

    See if you can join NCT07186296 on ClinicalTrials.gov

  13. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mfsmc-Hjwci, Baltimore, Maryland
    Locations
    202 in total
    Run by
    Pfizer

    See if you can join NCT07062965 on ClinicalTrials.gov

  14. The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

    The investigators propose a randomized controlled clinical trial in 250 women with a history of early stage breast cancer who are overweight or obese with insomnia to test whether a brief, cognitive-behavioral intervention for insomnia (CBT-I) prior to behavioral weight loss (CBT-I+BWL) is superior…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns Hopkins, Baltimore, Maryland
    Locations
    4 in total
    Run by
    Johns Hopkins University

    See if you can join NCT05780814 on ClinicalTrials.gov

  15. GammaPod Dose Escalation Radiation for Early Stage Breast Cancer

    The GammaPod machine was made by Xcision Medical Systems and is already FDA cleared to deliver focused radiation within the breast. Unlike current radiation machines, the GammaPod was designed specifically for treating breast cancer. The GammaPod can pinpoint radiation to the tumor bed in the breas…

    Stage
    Not phased
    Ages
    45 and older
    Site
    UMMC, Baltimore, Maryland
    Locations
    4 in total
    Run by
    University of Maryland, Baltimore

    See if you can join NCT04234386 on ClinicalTrials.gov

  16. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  17. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

    The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Weinberg Center at Mercy, Baltimore, Maryland
    Locations
    58 in total
    Run by
    Exact Sciences Corporation

    See if you can join NCT06401421 on ClinicalTrials.gov

  18. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Baltimore, Maryland
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  19. Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

    The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to co…

    Stage
    Phase 2
    Ages
    50 and older
    Site
    Maryland Proton Treatment Center, Baltimore, Maryland
    Locations
    9 in total
    Run by
    Proton Collaborative Group

    See if you can join NCT01766297 on ClinicalTrials.gov

  20. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Mercy Medical Center, Baltimore, Maryland
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

  21. A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

    This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Maryland Medical Center (UMMC), Baltimore, Maryland
    Locations
    13 in total
    Run by
    Processa Pharmaceuticals

    See if you can join NCT06568692 on ClinicalTrials.gov

  22. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to char…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins, Baltimore, Maryland
    Locations
    4 in total
    Run by
    AtlasMedx, Incorporated

    See if you can join NCT04503265 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.